pharmaphorum November 12, 2024
Phil Taylor

AstraZeneca plans to invest a whopping $3.5 billion to expand its R&D and manufacturing operations in the US by 2026, as part of a drive to raise its revenues to $80 billion by the end of the decade.

The programme – part of the pharma group’s Ambition 2030 effort – will include the construction of a new R&D centre at Kendall Square in the heart of the biopharma hub in Cambridge, Massachusetts, and a biologics manufacturing facility in Maryland.

There will also be expansion of cell therapy manufacturing capacity on “the West and East coasts,” as well as specialty manufacturing in Texas, according to AZ, which said $2 billion of the investment is earmarked for the creation of more than...

Today's Sponsors

LEK
ZeOmega

Today's Sponsor

LEK

Continue Reading

 
Topics: Biotechnology, Investments, Pharma, Pharma / Biotech, Trends
Related Articles:
Bariatric Surgeons Being Put Out of Work by GLP-1 Drugs
The CMS NHE 2023 Report: An Incomplete Picture at a Pivotal Time
Pharma At A Crossroads: Navigating Cost Pressures And Regulatory Shifts In 2025
Q&A: Proposed changes to Social Security Act would recognize pharmacists as healthcare providers
Why Walgreens Is Reportedly Considering a Private Equity Buyer

Share This Article